Creative Medical Technology Holdings (CELZ) announced it has completed enrollment and treatment across all cohorts of its FDA-cleared ADAPT trial evaluating CELZ-201. The update is a positive clinical development milestone, though the article provides no efficacy/safety results or quantified outcomes.
Creative Medical Technology Holdings (CELZ) announced it has completed enrollment and treatment across all cohorts of its FDA-cleared ADAPT trial evaluating CELZ-201. The update is a positive clinical development milestone, though the article provides no efficacy/safety results or quantified outcomes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
